FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2008
Commission File Number 0-16174
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
--------------------------------------
(Translation of registrant's name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 49131 Israel
-------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F X Form 40-F
------ ------
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
-----------------
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):
-----------------
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also hereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
---------- ----------
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g(3)-2(b): 82-
-----------
[GRAPHIC OMITTED][GRAPHIC OMITTED]
________________________________________________________________________________
Contact: Elana Holzman Teva Pharmaceutical Industries Ltd. 972 (3) 926-7554
Kevin Mannix Teva North America (215) 591-8912
FOR IMMEDIATE RELEASE
---------------------
TEVA TO REPORT FIRST QUARTER 2008 FINANCIAL
RESULTS ON MAY 6, 2008
CONFERENCE CALL SCHEDULED FOR 8:00 AM ET
Jerusalem, Israel, April 23, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ:
TEVA) announced today that it will release its first quarter 2008 financial
results on Tuesday, May 6, 2008.
Teva will host a conference call and live webcast on that same day, at 8:00 am
ET to discuss its first quarter 2008 results and overall business environment. A
Question & Answer session will follow this discussion. The earnings release will
be available on Teva's web site at www.tevapharm.com prior to the call.
Investors and other interested parties may access a live webcast through Teva's
web site at www.tevapharm.com. Please log in at least 10 minutes prior to the
conference call in order to download the applicable audio software. Following
the conclusion of the call, a replay of the webcast will be available within 24
hours at the Company's web site. Alternatively, a replay of the call can be
accessed until May 13, 2008 at 11:59 pm ET, by calling (201) 612-7415 outside
the U.S. or (877) 660-6853 in the U.S. The Pass Code to access the replay is:
Account #3055 and Conference ID #282223.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top
20 pharmaceutical companies in the world and is the world's leading generic
pharmaceutical company. The Company develops, manufactures and markets generic
and innovative human pharmaceuticals and active pharmaceutical ingredients, as
well as animal health pharmaceutical products. Over 80 percent of Teva's sales
are in North America and Europe.
Investor Relations:
5 Basel Street, P.O. Box 3190 Petach-Tikva 49131, Israel
Tel: 972-3-926-7281 Fax: 972-3-926-7519 www.tevapharm.com
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Registrant)
By: /s/ Dan Suesskind
---------------------------------------
Name: Dan Suesskind
Title: Chief Financial Officer
Date: April 23, 2008